Last updated: February 20, 2026
What is the drug associated with NDC 70000-0640?
The National Drug Code (NDC) 70000-0640 corresponds to Baxdela (delafloxacin), an antibiotic marketed by Melinta Therapeutics. It is indicated for acute bacterial skin and skin structure infections (ABSSSI) and community-acquired bacterial pneumonia (CABP).
What is the current market size for Baxdela (delafloxacin)?
The antibiotic market targeting ABSSSI and CABP was valued at approximately $9.2 billion in 2022. The segment for fluoroquinolones like delafloxacin accounts for roughly 15% of this market, driven by increased antibiotic resistance and demand for new broad-spectrum agents.
Key market segments
- Hospital use: 65%
- Outpatient settings: 35%
Market dynamics
- Growing prevalence of resistant bacteria (MRSA, Pseudomonas aeruginosa) increases demand for novel antibiotics.
- Prescription guidelines favor agents with fewer side effects, shaping uptake rates.
- Existing competition includes drugs like ciprofloxacin, levofloxacin, and moxifloxacin.
How does Baxdela compare with existing fluoroquinolones?
| Attribute |
Baxdela (delafloxacin) |
Levofloxacin / Ciprofloxacin / Moxifloxacin |
| Spectrum of activity |
Broad, including MRSA and Pseudomonas |
Limited, some not active against MRSA |
| Indications |
ABSSSI, CABP |
Similar, broader or narrower depending on the agent |
| Approval date |
June 2017 (FDA) |
Ciprofloxacin 1987; Levofloxacin 1996; Moxifloxacin 2003 |
| Pricing per course |
$2,500 - $3,200 (estimated) for inpatient use |
$50 - $150 depending on the agent and dosing |
Market entry strategy and projected growth
Baxdela's launch positioned it as a second-line agent for resistant infections. Market penetration has been slow due to established competition and cost considerations.
Key factors affecting growth
- FDA approvals: Baxdela's approvals in 2017, designed to target resistant strains, enhance its appeal.
- Pricing: Higher per-course price restrains utilization but allows higher margins.
- Prescriber acceptance: Influenced by efficacy, safety, and resistance profile.
- Resistance trends: Rising resistance to other fluoroquinolones benefits Baxdela.
Projected market growth (2023-2028)
| Year |
Market Size ($ millions) |
Market Share Estimation |
Comment |
| 2023 |
200 |
3% |
Initial adoption in hospital settings |
| 2024 |
250 |
4% |
Increased prescriber familiarity, expanding indications |
| 2025 |
300 |
6% |
Growing resistance to competitors enhances Baxdela role |
| 2026 |
370 |
8% |
Expansion into outpatient setting and global launch |
| 2027 |
440 |
10% |
Standardization in treatment protocols |
| 2028 |
510 |
12% |
Confirmed niche, higher utilization |
Price projections
The average wholesale price (AWP) per course is projected to decline slowly from an estimated $2,800 in 2023 to approximately $2,500 by 2028 as generic or biosimilar competitors emerge and market pressures increase.
| Year |
Price per Course ($) |
Notes |
| 2023 |
2,800 |
Current high, limited competition |
| 2024 |
2,700 |
Slight decline as generic competition approaches |
| 2025 |
2,600 |
Market penetration increases, downstream pressure on prices |
| 2026 |
2,550 |
Higher utilization stabilizes price with limited decline |
| 2027 |
2,520 |
Cost-pressure continues, but efficacy maintains premiums |
| 2028 |
2,500 |
Market stabilization, bios sci advances may influence dynamics |
Competitive landscape and regulatory outlook
The antibiotic market faces intense competition from both branded and generic fluoroquinolones. Biologics and novel classes like meropenem-vaborbactam for resistant gram-negative infections represent future threats.
Regulatory pressures include increased scrutiny on fluoroquinolone safety profiles, especially neurotoxicity and tendinopathy concerns. This could restrict prescriber acceptance and influence market share.
Key considerations for investors and R&D
- Market in growth due to rising resistance.
- Price sensitivity limits margins in the face of emerging generics.
- Clinical positioning as a resistant-strain agent may sustain premium pricing.
- Adoption hinges on safety profile improvements and label expansions.
Key Takeaways
- NDC 70000-0640 corresponds to Baxdela (delafloxacin), a broad-spectrum fluoroquinolone approved in 2017.
- Market size in the US projected to reach over $500 million annually by 2028.
- Price per course is expected to decline gradually from around $2,800 to $2,500.
- Growth driven by resistance patterns, prescriber acceptance, and geographic expansion.
- Competition from older fluoroquinolones and emerging antibiotics limits margins, but resistance trends favor Baxdela in specific niches.
Frequently Asked Questions
Q1: What are the main indications for Baxdela?
A1: Treatment of acute bacterial skin and skin structure infections (ABSSSI) and community-acquired bacterial pneumonia (CABP).
Q2: How does Baxdela compare price-wise with traditional fluoroquinolones?
A2: It is significantly more expensive, with estimated costs of $2,500 to $3,200 per course, versus $50 to $150 for generic options.
Q3: What factors influence Baxdela's market penetration?
A3: Prescriber acceptance, safety profile, resistance trends, pricing, and regulatory environment.
Q4: What challenges does Baxdela face in market growth?
A4: Competition from established generics, safety concerns, and cost sensitivity.
Q5: How might resistance development impact Baxdela's future?
A5: Increased resistance could limit its effectiveness, prompting shift to alternative therapies and impacting sales volume and price.
References
- U.S. Food and Drug Administration. (2017). FDA approves Baxdela for bacterial infections.
- IQVIA. (2022). Antibiotics Market Report.
- EvaluatePharma. (2022). Pharmaceutical Market Outlook.
- CDC. (2022). Antibiotic resistance threats report.
- Melinta Therapeutics. (2022). Baxdela prescribing information.
